Abstract:This paper is a personal account on the discovery and characterization of the 5-HT2C receptor (first known as the 5-HT1C receptor) over 30 years ago and how it translated into a number of unsuspected features for a G protein-coupled receptor (GPCR) and a diversity of clinical applications. The 5-HT2C receptor is one of the most intriguing members of the GPCR superfamily. Initially referred to as 5-HT1CR, the 5-HT2CR was discovered while studying the pharmacological features and the distribution of [3H]mesulergine-labelled sites, primarily in the brain using radioligand binding and slice autoradiography. Mesulergine (SDZ CU-085), was, at the time, best defined as a ligand with serotonergic and dopaminergic properties. Autoradiographic studies showed remarkably strong [3H]mesulergine-labelling to the rat choroid plexus. [3H]mesulergine-labelled sites had pharmacological properties different from, at the time, known or purported 5-HT receptors. In spite of similarities with 5-HT2 binding, the new binding site was called 5-HT1C because of its very high affinity for 5-HT itself. Within the following 10 years, the 5-HT1CR (later named 5-HT2C) was extensively characterised pharmacologically, anatomically and functionally: it was one of the first 5-HT receptors to be sequenced and cloned. The 5-HT2CR is a GPCR, with a very complex gene structure. It constitutes a rarity in the GPCR family: many 5-HT2CR variants exist, especially in humans, due to RNA editing, in addition to a few 5-HT2CR splice variants. Intense research led to therapeutically active 5-HT2C receptor ligands, both antagonists (or inverse agonists) and agonists: keeping in mind that a number of antidepressants and antipsychotics are 5-HT2CR antagonists/inverse agonists. Agomelatine, a 5-HT2CR antagonist is registered for the treatment of major depression. The agonist Lorcaserin is registered for the treatment of aspects of obesity and has further potential in addiction, especially nicotine/ smoking. There is good evidence that the 5-HT2CR is involved in spinal cord injury-induced spasms of the lower limbs, which can be treated with 5-HT2CR antagonists/inverse agonists such as cyproheptadine or SB206553. The 5-HT2CR may play a role in schizophrenia and epilepsy. Vabicaserin, a 5-HT2CR agonist has been in development for the treatment of schizophrenia and obesity, but was stopped. As is common, there is potential for further indications for 5-HT2CR ligands, as suggested by a number of preclinical and/or genome-wide association studies (GWAS) on depression, suicide, sexual dysfunction, addictions and obesity. The 5-HT2CR is clearly affected by a number of established antidepressants/antipsychotics and may be one of the culprits in antipsychotic-induced weight gain.

Molecular biology of 5-HT receptors

Molecular, pharmacological and functional diversity of 5-HT receptors

Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation

GPCRs steer G<sub>i</sub> and G<sub>s</sub> selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors

5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome

Structural Basis for Molecular Recognition at Serotonin Receptors

The discovery, structure, and function of 5-HTR1E serotonin receptor

Diverse signalling by 5-hydroxytryptamine (5-HT) receptors

A review of central 5-HT receptors and their function

Modern 5-HT receptor classification and 5-HT based drugs

Structure, Function, and Pharmaceutical Ligands of 5-Hydroxytryptamine 2B Receptor

5-HT Receptor-Associated Protein Networks: New Targets for Drug Discovery in Psychiatric Disorders?

Targeting the 5-HT system: Potential side effects

The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor Subunit

5-HT Receptor Regulation of Neurotransmitter Release

Structural insights into the lipid and ligand regulation of serotonin receptors

The 5-Hydroxytryptamine signaling map: an overview of serotonin-serotonin receptor mediated signaling network

5-Hydroxytryptamine (5-HT) Receptor Subtypes in Invertebrates

A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment

Subset specification of central serotonergic neurons

Embracing diversity in the 5-HT neuronal system